Measuring Progress in Precision Oncology
- PMID: 38213297
- DOI: 10.1158/2159-8290.CD-23-1237
Measuring Progress in Precision Oncology
Abstract
In this issue of Cancer Discovery, Suehnholz and colleagues describe their efforts to quantify the gradual yet steady progress of precision oncology by surveying the regulatory approvals of targeted cancer therapies, and thus the actionability of corresponding molecular alterations in clinical practice, over more than 20 years. Their work also suggests a relationship between the discovery of candidate therapeutic targets through comprehensive tumor profiling and molecularly guided cancer drug development. See related article by Suehnholz et al., p. 49 (5).
©2023 American Association for Cancer Research.
Comment on
-
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.Cancer Discov. 2024 Jan 12;14(1):49-65. doi: 10.1158/2159-8290.CD-23-0467. Cancer Discov. 2024. PMID: 37849038 Free PMC article.